Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results

M. Tiseo; S. Popat; H.R. Kim; M-J. Ahn; J.C. Yang; J-Y. Han; M.J. Hochmair; K.H. Lee; A. Delmonte; M.R. Garcia Campelo; D-W. Kim; F. Griesinger; E. Felip; R. Califano; A.I. Spira; S.N. Gettinger; H.M. Lin; Y. Liu; F. Vranceanu; D.R. Camidge

doi:10.1016/j.annonc.2022.02.038

YUHSpace

BROWSE

Cited 0 times in

Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results

Authors: M. Tiseo ; S. Popat ; H.R. Kim ; M-J. Ahn ; J.C. Yang ; J-Y. Han ; M.J. Hochmair ; K.H. Lee ; A. Delmonte ; M.R. Garcia Campelo ; D-W. Kim ; F. Griesinger ; E. Felip ; R. Califano ; A.I. Spira ; S.N. Gettinger ; H.M. Lin ; Y. Liu ; F. Vranceanu ; D.R. Camidge